Health TrialsbyHealthPanel

Impact of Echocardiography on Management of Critically Ill Neonates

ConditionsCritical IllnessEchocardiographyNeonatology
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-28
SponsorSahar Abozkaly Mahmoud

About this trial

The goal of the study was to estimate the outcome (mortality and morbidity) among hemodynamically unstable neonates, as well as the time to return to hemodynamic stability following the use of ECHO in the management of hemodynamically unstable neonates.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

All neonates ( age 0 to 28 days) admitted to the NICU of Sohag University Hospital during the period of the study in whom manifestations of hemodynamic instability or critical illness were elected regardless of gestational age, weight, gender, or type of disease.

Disqualifiers

Failure to obtain informed consent .

Presence of congenital heart disease apart from PDA , PFO & small ASD .

Trial population

Neonates ( age 0 to 28 days) admitted to the NICU of Sohag University Hospital during the period of the study

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Echocardiography

    Device

    Functional echocardiography assessment

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Group 11 intervention
Group B: Group 21 intervention

Trial outcomes

Primary outcomes

1

Functional echocardiography ( ejection fraction using M mode echocardiography)

Time frame
Repeat echocardiographic assessment on a daily basis ( 24 hours interval)
2

Functional echocardiography fraction shortening by M mode echocardiography

Time frame
Repeat echocardiographic assessment on a daily basis ( 24 hours interval)
3

Assessment of ductus arteriosus ( diameter, shunt directionality ) by 2D and color doppler echocardiography

Time frame
Repeat echocardiographic assessment 5 days after the first echo assessment
4

Assessment of pulmonary hypertension

Using peak tricuspid regurgitation velocity by colour doppler

Time frame
Repeat echocardiographic assessment on a daily basis ( 24 hours interval) following proposed treatment of pulmonary hypertension

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sahar Abozkaly Mahmoud

Lead sponsor

Sohag University

Sponsor institution

Source ClinicalTrials.gov
Apply now